References
- Beutler B, Biron C, Carroll M, Cyster J, Gerard C, Gordon S, Lanier L, Lehrer R, McGhee J, Medzhitov R, Springer T, Yokoyama W. Innate Immunity. Immuno Biology, CA Janeway, Jr, P Travers, M Walport, MJ Shlomchik. Garland Science, New York 2005; 37–100
- Takeda K, Akira S. Toll-like receptors: ligands and signaling. The innate immune response to infection, SHE Kaufmann, R Medzhitov, S Gordon. ASM Press, Washington, D.C. 2004; 257–70
- Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138–50
- Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004; 4: 512–20
- Cristofaro P, Opal SM. Role of toll-like receptors in infection and immunity. Drugs 2006; 66: 15–29
- Chamberlain NR. Microbiology lecture. Available from: www.kcom.edu/faculty/chamberlain/website/lectures/lecture/sepsis.htm.
- Steensberg A, Fischer CP, Keller C, Møller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003; 285: E433–7
- Opal SM, Huber CE. The role of interleukin-10 in critical illness. Curr Opin Infect Dis 2000; 13: 221–6
- Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 2002; 20: 125–63
- Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000; 117: 1162–72
- Lazar G, Jr, Lazar G, Agarwal MK. Modification of septic shock in mice by the antiglucocoticoid RU-38486. Circ Shock 1992; 36: 180–4
- FDA Public Health Advisory. Sepsis and medical abortion. Available from: www.fda.gov/CDER/DRUG/advisory/mifeprex.htm.
- Cadepond F, Ulmann A, Baulieu E. RU486 (Mifepristone: mechanisms of action and clinical uses). Ann Rev Med 1997; 48: 129–56
- Rorbye C, Petersen IS, Nilas L. Postpartum Clostridium sordellii infection associated with fatal toxic shock syndrome. Acta Obstet Gynecol Scand 2000; 79: 1134–5
- Sarkar NN. Mifepristone. Bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol 2002; 101: 113–20
- He K, Woolf TF, Hollenbeerg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 1999; 288: 791–7
- Miech RP. Pathophysiology of Mifepristone-induced septic shock due to Clostridium sordellii. Ann Pharmacother 2005; 39: 1483–8
- Miech RP. FDA: Emerging Clostridial Disease Workshop, May 11, 2006, Atlanta, GA. Available from: www.fda.gov/cder/meeting/clostridial/meeting_summary.pdf.
- Schirmer J, Aktories K. Large clostridial cytotoxins: cellular biology of Rho/Ras-glucosylating toxins. Biochim Biophys Acta 2004; 1673: 66–74